Pediatric low-grade gliomas can be molecularly stratified for risk
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractPediatric low-grade gliomas (PLGGs) consist of a number of entities with overlapping histological features. PLGGs have much better prognosis than the adult counterparts, but a significant proportion of PLGGs suffers from tumor progression and recurrence. It has been shown that pediatric and adult low-grade gliomas are molecularly distinct. Yet the clinical significance of some of newer biomarkers discovered by genomic studies has not been fully investigated. In this study, we evaluated in a large cohort of 289 PLGGs a list of biomarkers and examined their clinical relevance. TERT promoter (TERTp), H3F3A and BRAF V600E mutations were detected by direct sequencing. ATRX nuclear loss was examined by immunohistochemistry. CDKN2A deletion, KIAA1549-BRAF fusion, and MYB amplification were determined by fluorescence in situ hybridization (FISH). TERTp, H3F3A, and BRAF V600E mutations were identified in 2.5, 6.4, and 7.4% of PLGGs, respectively. ATRX loss was found in 4.9% of PLGGs. CDKN2A deletion, KIAA1549-BRAF fusion and MYB amplification were detected in 8.8, 32.0 and 10.6% of PLGGs, respectively. Survival analysis revealed that TERTp mutation, H3F3A mutation, and ATRX loss were significantly associated with poor PFS (p < 0.0001, p < 0.0001, and p = 0.0002) and OS (p < 0.0001, p < 0.0001, and p < 0.0001). BRAF V600E was associated with shorter PFS (p = 0.011) and OS (p = 0.032) in a subset of PLGGs. KIAA1549-BRAF fusion was a good prognostic marker for longer PFS (p = 0.0017) and OS (p = 0.0029). MYB amplification was also a favorable marker for a longer PFS (p = 0.040). Importantly, we showed that these molecular biomarkers can be used to stratify PLGGs into low- (KIAA1549-BRAF fusion or MYB amplification), intermediate-I (BRAF V600E and/or CDKN2A deletion), intermediate-II (no biomarker), and high-risk (TERTp or H3F3A mutation or ATRX loss) groups with distinct PFS (p < 0.0001) and OS (p < 0.0001). This scheme should aid in clinical decision-making.
All Author(s) ListRui Ryan Yang, Abudumijiti Aibaidula, Wei‑wei Wang, Aden Ka‑Yin Chan, Zhi‑feng Shi, Zhen‑yu Zhang, Danny Tat Ming Chan, Wai Sang Poon, Xian‑zhi Liu, Wen‑cai Li, Rui‑qi Zhang, Yan‑Xi Li, Nellie Yuk‑Fei Chung, Hong Chen, Jingsong Wu, Liangfu Zhou, Kay Ka‑Wai Li, Ho‑Keung Ng
Journal nameActa Neuropathologica
Year2018
Month10
Volume Number136
Issue Number4
Pages641 - 655
ISSN0001-6322
LanguagesEnglish-United Kingdom
KeywordsBRAF, ATRX, Pediatric low-grade gliomas, Molecular risk stratification, H3F3A, CDKN2A

Last updated on 2020-27-06 at 01:56